MOLECULAR ASPECTS OF THE BONE METASTASTASES DEVELOPMENT IN PROSTATE CANCER
Keywords:
prostate cancer, bone metastases, immunophenotype, androgen receptors, neoangiogenesis, heat shock proteins, matrix metalloproteinase 1, inflammation, osteoblastic markers, apoptosis
Abstract
This review is devoted to the topical issue of modern medicine – the molecular mechanisms and factors for the development of bone metastases of malignant tumors, in particular prostate cancer. The recent publication on the formation and progression of prostate cancer bone metastases were analyzed in this study.
The expression of some molecular markers in tumor and metastatic tissue and their role in tumor progression were also analyzed in this study. A common concept for the development of specific metastases is a seed and soil theory. According to this concept, circulating cancer cells recognize some organs as the optimal microenvironment for their development. However, the molecular mechanisms of this phenomenon remain unknown.
Molecular and genetic features of the androgen receptors expression in the tumor and their role in metastatic tissue were summarized and compared in this study. We also demonstrated the effect of these receptors on the development of osteoblastic metastases and castration-resistant prostate cancer. Authors analyzed and summarized data about the role of p53 protein, Bax and activated caspase 3 in apoptosis, mechanisms of neoangiogenesis and remodeling of tumor connective tissue with matrix metalloproteinase 1, the presence of collagen type I and osteonectin in neoplastic tissues and the role of inflammation in metastasis development. Functions of heat shock proteins with molecular masses of 70 and 90 kDa and their role in tumor and metastatic tissue were also analyzed. Thus, the study complements and summarizes the data on the development of bone metastases of prostate cancer. The study analyzed the molecular characteristics of prostate cancer during its metastatic spread.
Downloads
Download data is not yet available.
References
1. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80:1588–1594.
2. Bussard KM, Gay CV, Mastro AM. The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev. 2008;27:41–55.
3. Buijs JT, van der Pluijm G. Osteotropic cancers: From primary tumor to bone. Cancer Lett. 2009;273:177–193.
4. Langley RR, Fidler IJ. The seed and soil hypothesis revisited – The role of tumor-stroma interactions in metastasis to different organs. Int J Cancer. 2011;128:2527–2535.
5. Guise T. Examining the metastatic niche: targeting the microenvironment. Semin Oncol. 2010;37(S2):S2–S14.
6. Logothetis C, Morris MJ, Den R, Coleman RE. Current perspectives on bone metastases in castrate-resistant prostate cancer. Cancer Metastasis Rev. 2018;37(1):189–196.
7. Logothetis CJ, Lin S-H. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer. 2005;5:21–28.
8. Faltermeier CM, Drake JM, Clark PM, Smith BA, Zong Y, Volpe C, Mathis C, Morrissey C, Castor B, Huang J, Witte ON. Functional screen identifies kinases driving prostate cancer visceral and bone metastasis. Proc Natl Acad Sci U S A. 2016;113(2):E172–E181.
9. Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, Blackburn J, Arora T, Brill I, Kilgore ML. Mortality following bone metastasis and skeletal-related events among women with breast cancer: A population-based analysis of U.S. Medicare beneficiaries, 1999-2006. Breast Cancer Res Treat. 2012;131:231–238.
10. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;360:1655–1664.
11. Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem. 2004;91:718–729.
12. Yin JJ, Mohammad KS, Käkönen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, Guise TA. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A. 2003;100:10954–10959.
13. Nelson JB, Nguyen SH, Wu-Wong JR, Opgenorth TJ, Dixon DB, Chung LW, Inoue N. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology. 1999;53:1063–1069.
14. Ottewell PD, Wang N, Meek J, Fowles CA, Croucher PI, Eaton CL, Holen I. Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocr Relat Cancer. 2014;21:769–781.
15. Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res. 2005;65:8274–8285.
16. Cohen P, Peehl DM, Graves HCB, Rosenfeld RG. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol. 1994;142:407–415.
17. Cramer SD, Chen Z, Peehl DM. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol. 1996;156:526–531.
18. Briganti A, Suardi N, Gallina A, Abdollah F, Novara G, Ficarra V, Montorsi F. Predicting the risk of bone metastasis in prostate cancer. Cancer Treat Rev. 2014;40(1):3–11.
19. Hoque A, Chen H, Xu XC. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev. 2008;17:88–94.
20. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 2005;115:959–968.
21. Manolagas SC, O’Brien CA, Almeida M. The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol. 2013;9:699–712.
22. Wiren KM, Evans CA, Zhang X-W. Osteoblast differentiation influences androgen and estrogen receptor-alpha and - beta expression. J Endocrinol. 2002;175:683–694.
23. Chiang C, Chiu M, Moore AJ, Anderson PH, Ghasem-Zadeh A, McManus JF, Ma C, Seeman E, Clemens TL, Morris HA, Zajac JD, Davey RA. Mineralization and bone resorption are regulated by the androgen receptor in male mice. J Bone Miner Res. 2009;24(4):621–631.
24. Russell PK, Clarke MV, Cheong K, Anderson PH, Morris HA, Wiren KM, Zajac JD, Davey RA. Androgen receptor action in osteoblasts in male mice is dependent on their stage of maturation. J Bone Miner Res. 2015;30:809–823.
25. Chang C, Yeh S, Lee SO, Chang TM. Androgen receptor (AR) pathophysiological roles in androgen-related diseases in skin, bone/muscle, metabolic syndrome and neuron/immune systems: lessons learned from mice lacking AR in specific cells. Nucl Recept Signal. 2013;11:e001.
26. Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther. 2013;140(3):223–238.
27. Krieg M, Weisser H, Tunn S. Potential activities of androgen metabolizing enzymes in human prostate. J Steroid Biochem Mol Biol. 1995;53(1–6):395–400
28. Davey RA, Grossmann M. Androgen Receptor Structure, Function and Biology: From Bench to Bedside. Clin Biochem Rev. 2016;37(1):3–15.
29. Pihlajamaa P, Sahu B, Jänne OA. Determinants of Receptor- and Tissue-Specific Actions in Androgen Signaling. Endocr Rev. 2015;36(4):357–384.
30. Steers WD. 5α-reductase activity in the prostate. Urology. 2001;58(6 Suppl 1):17–24.
31. Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem. 2006;99:333–344.
32. Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol. 2018;73(5);715–723.
33. Cai Z, Chen W, Zhang J, Li H. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer. Int Urol Nephrol. 2018;50(10):1753–1764.
34. Wyatt AW, Gleave ME. Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med. 2015;7(7):878–894.
35. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447–4454.
36. Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol. 2015;67:470–479.
37. Antonarakis ES, Armstrong AJ, Dehm SM, Luo J. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. Prostate Cancer Prostatic Dis. 2016;19:231–241.
38. Ho SM, Leung YK, Chung I. Estrogens and antiestrogens as etiological factors and therapeutics for prostate cancer. Ann. N. Y. Acad. Sci. 2006;1089:177–193.
39. Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids. 2008;73(3):233–244.
40. Hartman J, Ström A, Gustafsson JÅ. Current concepts and significance of estrogen receptor β in prostate cancer. Steroids. 2012;77:1262–1266.
41. Daniels G, Gellert LL, Melamed J, Hatcher D, Li Y, Wei J, Wang J, Lee P. Decreased expression of stromal estrogen receptor α and β in prostate cancer. Am J Transl Res. 2014;6:140–146.
42. Pisolato R, Lombardi APG, Vicente CM, Lucas TFG, Lazari MFM, Porto CS. Expression and regulation of the estrogen receptors in PC-3 human prostate cancer cells. Steroids. 2016;107:74–86.
43. Bradshaw AD. Diverse biological functions of the SPARC family of proteins. Int. J. Biochem. Cell Biol. 2012;44:480–488.
44. Murphy-Ullrich JE, Sage EH. Revisiting the matricellular concept. Matrix Biol. 2014;37:1–14.
45. Rosset EM, Bradshaw AD. SPARC/Osteonectin in Mineralized Tissue. Matrix Biol. 2016;52–54:78–87.
46. Kelm RJ Jr, Mann KG. The collagen binding specificity of bone and platelet osteonectin is related to differences in glycosylation. J. Biol. Chem. 1991;266:9632–9639.
47. Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, Martin GR. Osteonectin, a bone-specific protein linking mineral to collagen. Cell. 1981;26:99–105.
48. Delany AM, Hankenson KD. Thrombospondin-2 and SPARC/osteonectin are critical regulators of bone remodeling. J. Cell Commun. Signal. 2009;3:227–238.
49. Trombetta JM, Bradshaw AD. SPARC/Osteonectin Functions to Maintain Homeostasis of the Collagenous Extracellular Matrix in the Periodontal Ligament. J Histochem Cytochem. 2010;58(10):871–879.
50. Ingber D, Folkman J. Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: role of extracellular matrix. J Cell Biol. 1989;109:317–330.
51. Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res. 2000;6(3):1140–1149.
52. Brekken RA, Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 2001;19:816–827.
53. Breton-Gorius J, Clezardin P, Guichard J, Debili N, Malaval L, Vainchenker W, Cramer EM, Delmas PD. Localization of platelet osteonectin at the internal face of the alpha-granule membranes in platelets and megakaryocytes. Blood. 1992;79:936–941.
54. Reed MJ, Puolakkainen P, Lane TF, Dickerson D, Bornstein P, Sage EH. Differential expression of SPARC and thrombospondin 1 in wound repair: immunolocalization and in situ hybridization. J. Histochem. Cytochem. 1993;41:1467–1477.
55. Sage H, Johnson C, Bornstein P. Characterization of a novel serum albuminbinding glycoprotein secreted by endothelial cells in culture. J Biol Chem. 1984;259:3993–4007.
56. McCabe NP, Kerr BA, Madajka M, Vasanji A, Byzova TV. Augmented Osteolysis in SPARC-Deficient Mice with Bone-Residing Prostate Cancer. Neoplasia. 2011;13(1):31–39.
57. Ruela-Arispe M L, Lane T F, Redmond D, Reilly M, Bolender RP, Kavanagh TJ, Sage EH. Expression of SPARC during development of the chicken chorioallantoic membrane: evidence for regulated proteolysis in vivo. Mol. Biol. Cell. 1995;6: 327–343.
58. Burns-Cox N, Avery NC, Gingell JC, Bailey AJ. Changes in collagen metabolism in prostate cancer: a host response that may alter progression. J Urol. 2001;166(5):1698–1701.
59. Gao J, Song J, Huang H, Li Z, Du Y, Cao J, Li M, Lv S, Lin H, Gong Y. Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer. J Exp Clin Cancer Res. 2010;29(1):28.
60. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52–67.
61. Hynes RO, Naba A. Overview of the matrisome – an inventory of extracellular matrix constituents and functions. Cold Spring Harb Perspect Biol. 2012;4(1):a004903.
62. Cierna Z, Mego M, Janega P, Karaba M, Minarik G, Benca J, Sedlácková T, Cingelova S, Gronesova P, Manasova D, Pindak D, Sufliarsky J, Danihel L, Reuben JM, Mardiak J. Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer. BMC Cancer. 2014;14:472.
63. Mohan V, Talmi-Frank D, Arkadash V, Papo N, Sagi I. Matrix metalloproteinase protein inhibitors: highlighting a new beginning for metalloproteinases in medicine. Metalloproteinases in medicine. 2016;3:31–47.
64. Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia. 2010;15:201–212.
65. Mannello F. What does matrix metalloproteinase-1 expression in patients with breast cancer really tell us? BMC Med. 2011;9:95.
66. Hu F, Zhang Y, Li M, Zhao L, Chen J, Yang S, Zhang X. BMP-6 inhibits the metastasis of MDA-MB-231 breast cancer cells by regulating MMP-1 expression. Oncol. Rep. 2016;35:1823–1830.
67. Liu M, Hu Y, Zhang M-F, Luo K-J, Xie X-Y, Wen J, Fu JH, Yang H. MMP1 promotes tumor growth and metastasis in esophageal squamous cell carcinoma. Cancer Letters. 2016;377(1):97–104.
68. Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, Reiss M, Massagué J, Kang Y. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev. 2009;23:1882–1894
69. Casimiro S, Mohammad KS, Pires R, Tato-Costa J, Alho I, Teixeira R, Carvalho A, Ribeiro S, Lipton A, Guise TA, Costa L. RANKL/RANK/MMP-1 Molecular Triad Contributes to the Metastatic Phenotype of Breast and Prostate Cancer Cells In Vitro. PLoS One. 2013;8(5):e63153.
70. Ozden F, Saygin C, Uzunaslan D, Onal B, Durak H, Aki H. Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival. J. Cancer Res. Clin. Oncol. 2013;39:1373–1382.
71. Bianchi ME. Damps, pamps and alarmins: all we need to know about danger. J. Leukoc. Biol. 2007;81:1–5.
72. Min HJ, Choe JW, Chang MY, Kim KS, Lee SY, Mun SK. The expression and correlation of Hsp 70 and Hsp 27 in serous middle ear effusion fluids of pediatric patients-a preliminary study. International Journal of Pediatric Otorhinolaryngology. 2017;101:145–149.
73. Wu J, Liu T, Rios Z, Mei Q, Lin X, Cao S. Heat Shock Proteins and Cancer. Trends Pharmacol. Sci. 2017;38:226–256.
74. Gabai VL, Budagova KR, Sherman MY. Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents. Oncogene. 2005;24:3328.
75. Jindal DG, Jindal V, Joshi S, Bhojia I, Chawdhr A. Heat shock proteins in pathology: A review. Journal of Pierre Fauchard Academy (India Section). 2016;30(3–4):84–87.
76. Helmbrecht K, Zeise E, Rensing L. Chaperons in cell cycle regulation and mitogenic signal transduction: a review. Cell Prolif. 2000;92:1564.
77. Ni L, Yang CS, Gioeli D, Frierson H, Toft DO, Paschal BM. FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells. Mol Cell Biol. 2010;30(5):1243–1253.
78. Heinlein CA, Chang CS. Androgen receptor in prostate cancer. Endocr. Rev. 2004;25:276–308.
79. Kurahashi T, Miyake H, Hara I, Fujisawa M. Expression of Major Heat Shock Proteins in Prostate Cancer: Correlation With Clinicopathological Outcomes in Patients Undergoing Radical Prostatectomy. The Journal of Urology. 2007;177(2):757–761.
80. Narula S, Tandon S, Baligar P, Singh SK, Tandon C. Human kidney stone matrix: Latent potential to restrain COM induced cytotoxicity and inflammatory response. Chemico-Biological Interactions. 2017; 278:114–122.
81. Melman A. Synthesis of Inorganic Nanoparticles Using Protein Templates. Fine Particles in Medicine and Pharmacy. New York: Springer US, 2012, 340 p.
82. Chen E, Xue D, Zhang W, Lin F, Pan Z. Extracellular heat shock protein 70 promotes osteogenesis of human mesenchymal stem cells through activation of the ERK signaling pathway. FEBS Letters. 2015;589(24, parn B):4088–4096.
83. Fong-Ngern K, Sueksakit K, Thongboonkerd V. Surface heat shock protein 90 serves as a potential receptor for calcium oxalate crystal on apical membrane of renal tubular epithelial cells. J Biol Inorg Chem. 2016;21(4):463–74.
84. Li K, Xue Y, Chen A, Jiang Y, Xie H, Shi Q, Zhang S, Ni Y. Heat Shock Protein 90 Has Roles in Intracellular Calcium Homeostasis, Protein Tyrosine Phosphorylation Regulation, and Progesterone-Responsive Sperm Function in Human Sperm. PLoS One. 2014;9(12):e115841.
85. Kato K, Adachi S, Matsushima-Nishiwaki R, Minamitani C, Natsume H, Katagiri Y, Hirose Y, Mizutani J, Tokuda H, Kozawa O, Otsuka T. Regulation by Heat Shock Protein 27 of Osteocalcin Synthesis in Osteoblasts. Endocrinology. 2011;152(5):1872–1882.
86. Spierings D, McStay G, Saleh M, Bender C, Chipuk J, Maurer U, Green DR. Connected to death: the (unexpurgated) mitochondrial pathway of apoptosis. Science. 2005;310(5745):66–67.
87. Wajant H. The Fas signaling pathway: more than a paradigm. Science. 2002;296(5573):1635–1636.
88. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26(9):1324–1337.
89. Hu J, Duan Z, Yu G, Wang S. Bcl-2 Inhibitors as Sensitizing Agents for Cancer Chemotherapy. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy. 2019:151–168.
90. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature. 2009;458:1127–1130.
91. Thornton C, Hagberg H. Fetal and Neonatal Physiology (Fifth Edition). London: Elsevier, 2017, 1928 p.
92. Chappell WH, Lehmann BD, Terrian DM, Abrams SL, Steelman LS, McCubrey JA. p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. Cell Cycle. 2012;11(24):4579–4588.
93. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2010;2:a001107.
94. Chang YJ, Linh NH, Shih YH, Yu HM, Li MS, Chen YR. Alzheimer's amyloid-beta sequesters caspase-3 in vitro via its C-terminal tail. ACS Chem Neurosci. 2016;7:1097–1106.
95. Flanagan L, Meyer M, Fay J, Curry S, Bacon O, Duessmann H, John K, Boland KC, McNamara DA, Kay EW, Bantel H, Schulze-Bergkamen H, Prehn JH. Low levels of caspase-3 predict favourable response to 5FU-based chemotherapy in advanced colorectal cancer: caspase-3 inhibition as a therapeutic approach. Cell Death Dis. 2016;7:e2087.
96. Rodríguez-Berriguete G, Galvis L, Fraile B, de Bethencourt FR, Martínez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M. Immunoreactivity to caspase-3, caspase-7, caspase-8, and caspase-9 forms is frequently lost in human prostate tumors. Human Pathology. 2012;43:229–237.
97. Ashkenazi A, Salvesen G. Regulated Cell Death: Signaling and Mechanisms. Annual Review of Cell and Developmental Biology. 2014;30:337–356.
98. Bleicken S, Landeta O, Landajuela A, Basanez G, García-Saez AJ. Proapoptotic Bax and Bak Proteins Form Stable Protein-permeable Pores of Tunable Size. The journal of biological chemistry. 2013;288(46):33241–33252.
99. Rostamzadeh A, Ghadimi T, Allahveisi A, Mohammadi M, Rezaei S, Rezaie MJ. The expression of Bax protein in the early stages of spinal cord injury in the sperm cells of rats. Polish Annals of Medicine. 2018;25(2):196–202.
100. Snigdha S, Smith ED, Prieto GA, Cotman CW. Caspase-3 activation as a bifurcation point between plasticity and cell death. Neuroscience Bulletin. 2012;28(1):14–24.
101. Hernández-Luna MA, Díaz de León-Ortega R, Hernández-Cueto DD, Gaxiola-Centeno R, Castro-Luna R, Martínez-Cristóbal L, Huerta-Yépez S, Luria-Pérez R. Bactofection of sequences encoding a Bax protein peptide chemosensitizes prostate cancer tumor cells. Bol Med Hosp Infant Mex. 2016;73(6):388–396.
102. Maji S, Panda S, Samal S K, Shriwas O, Rath R, Pellecchia M, Emdad L, Das SK, Fisher PB, Dash R. Bcl-2 Antiapoptotic Family Proteins and Chemoresistance in Cancer. Advances in Cancer Research. 2018;137:37–75.
103. Westphal D, Kluck RM, Dewson G. Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis. Cell Death & Differentiation. 2014;21(2):196–205.
104. Yuan Z, Jiang H, Zhu X, Liu X, Li L. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer. Biomedicine & Pharmacotherapy. 2017;89:227–232.
105. Kervancioglu E, Kosan M, Erinanc H, Gonulalan U, Oguzulgen AI, Coskun EZ, Ozkardes H. Predictive values of vascular endothelial growth factor and microvessel-density levels in initial biopsy for prostate cancer. The Kaohsiung Journal of Medical Sciences. 2016;32(2):74–79.
106. Liu ZQ, Fang JM, Xiao YY, Zhao Y, Cui R, Hu F, Xu Q. Prognostic role of vascular endothelial growth factor in prostate cancer: A systematic review and meta-analysis. Int J Clin Exp Med. 2015;8:2289–2298.
107. Nordby Y, Andersen S, Richardsen E, Ness N, Al-Saad S, Melbø-Jørgensen C, Patel HR, Dønnem T, Busund LT, Bremnes RM. Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy. Prostate. 2015;75:1682–1693.
108. Rivera-Pérez J, Monter-Vera MDR, Barrientos-Alvarado C, Toscano-Garibay JD, Cuesta-Mejías T, Flores-Estrada J. Evaluation of VEGF and PEDF in prostate cancer: A preliminary study in serum and biopsies. Oncology Letters. 2018;15:1072–1078.
109. Djordjevic S, Driscoll PC. Targeting VEGF signalling via the neuropilin co-receptor. Drug Discov. Today. 2013;18:447–455.
110. Shibuya. M. VEGF-VEGFR signals in health and disease. Biomol Ther. 2014;22:1–9.
111. Roberts E, Cossigny DAF, Quan GMY. The Role of Vascular Endothelial Growth Factor in Metastatic Prostate Cancer to the Skeleton. Prostate Cancer. 2013:418340.
112. Gerber H-P, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossifcation and angiogenesis during endochondral bone formation. Nature Medicine. 1999;5(6):623–628.
113. Cossigny D, Quan GMY. In vivo animal models of spinal metastasis. Cancer and Metastasis Reviews. 2012;31(1):99–108.
114. Curtin P, Youm H, Salih E. Tree-dimensional cancerbone metastasis model using ex-vivo co-cultures of live calvarial bones and cancer cells. Biomaterials. 2012;33(4):1065–1078.
115. Karan D, Dubey S. From Inflammation to Prostate Cancer: The Role of Inflammasomes. Adv Urol. 2016;2016:3140372.
116. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867.
117. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–890.
118. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY, Sun HC. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008;26:2707–2716.
119. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362:875–885.
120. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell. 2009;15:416–428.
121. Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Molecular Cancer. 2013;12(1);86.
122. Mishra A, Shiozawa Y, Pienta KJ, Taichman RS. Homing of cancer cells to the bone. Cancer Microenviron. 2011,4:221–235.
123. Scimeca M, Urbano N, Rita B, Mapelli SN, Catapano CV, Carbone GM, Ciuffa S, Tavolozza M, Schillaci O, Mauriello A, Bonanno E. Prostate Osteoblast-Like Cells: A Reliable Prognostic Marker of Bone Metastasis in Prostate Cancer Patients. Contrast Media Mol Imaging. 2018;2018:9840962.
2. Bussard KM, Gay CV, Mastro AM. The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev. 2008;27:41–55.
3. Buijs JT, van der Pluijm G. Osteotropic cancers: From primary tumor to bone. Cancer Lett. 2009;273:177–193.
4. Langley RR, Fidler IJ. The seed and soil hypothesis revisited – The role of tumor-stroma interactions in metastasis to different organs. Int J Cancer. 2011;128:2527–2535.
5. Guise T. Examining the metastatic niche: targeting the microenvironment. Semin Oncol. 2010;37(S2):S2–S14.
6. Logothetis C, Morris MJ, Den R, Coleman RE. Current perspectives on bone metastases in castrate-resistant prostate cancer. Cancer Metastasis Rev. 2018;37(1):189–196.
7. Logothetis CJ, Lin S-H. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer. 2005;5:21–28.
8. Faltermeier CM, Drake JM, Clark PM, Smith BA, Zong Y, Volpe C, Mathis C, Morrissey C, Castor B, Huang J, Witte ON. Functional screen identifies kinases driving prostate cancer visceral and bone metastasis. Proc Natl Acad Sci U S A. 2016;113(2):E172–E181.
9. Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, Blackburn J, Arora T, Brill I, Kilgore ML. Mortality following bone metastasis and skeletal-related events among women with breast cancer: A population-based analysis of U.S. Medicare beneficiaries, 1999-2006. Breast Cancer Res Treat. 2012;131:231–238.
10. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;360:1655–1664.
11. Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem. 2004;91:718–729.
12. Yin JJ, Mohammad KS, Käkönen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, Guise TA. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A. 2003;100:10954–10959.
13. Nelson JB, Nguyen SH, Wu-Wong JR, Opgenorth TJ, Dixon DB, Chung LW, Inoue N. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology. 1999;53:1063–1069.
14. Ottewell PD, Wang N, Meek J, Fowles CA, Croucher PI, Eaton CL, Holen I. Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocr Relat Cancer. 2014;21:769–781.
15. Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res. 2005;65:8274–8285.
16. Cohen P, Peehl DM, Graves HCB, Rosenfeld RG. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol. 1994;142:407–415.
17. Cramer SD, Chen Z, Peehl DM. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol. 1996;156:526–531.
18. Briganti A, Suardi N, Gallina A, Abdollah F, Novara G, Ficarra V, Montorsi F. Predicting the risk of bone metastasis in prostate cancer. Cancer Treat Rev. 2014;40(1):3–11.
19. Hoque A, Chen H, Xu XC. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev. 2008;17:88–94.
20. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 2005;115:959–968.
21. Manolagas SC, O’Brien CA, Almeida M. The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol. 2013;9:699–712.
22. Wiren KM, Evans CA, Zhang X-W. Osteoblast differentiation influences androgen and estrogen receptor-alpha and - beta expression. J Endocrinol. 2002;175:683–694.
23. Chiang C, Chiu M, Moore AJ, Anderson PH, Ghasem-Zadeh A, McManus JF, Ma C, Seeman E, Clemens TL, Morris HA, Zajac JD, Davey RA. Mineralization and bone resorption are regulated by the androgen receptor in male mice. J Bone Miner Res. 2009;24(4):621–631.
24. Russell PK, Clarke MV, Cheong K, Anderson PH, Morris HA, Wiren KM, Zajac JD, Davey RA. Androgen receptor action in osteoblasts in male mice is dependent on their stage of maturation. J Bone Miner Res. 2015;30:809–823.
25. Chang C, Yeh S, Lee SO, Chang TM. Androgen receptor (AR) pathophysiological roles in androgen-related diseases in skin, bone/muscle, metabolic syndrome and neuron/immune systems: lessons learned from mice lacking AR in specific cells. Nucl Recept Signal. 2013;11:e001.
26. Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther. 2013;140(3):223–238.
27. Krieg M, Weisser H, Tunn S. Potential activities of androgen metabolizing enzymes in human prostate. J Steroid Biochem Mol Biol. 1995;53(1–6):395–400
28. Davey RA, Grossmann M. Androgen Receptor Structure, Function and Biology: From Bench to Bedside. Clin Biochem Rev. 2016;37(1):3–15.
29. Pihlajamaa P, Sahu B, Jänne OA. Determinants of Receptor- and Tissue-Specific Actions in Androgen Signaling. Endocr Rev. 2015;36(4):357–384.
30. Steers WD. 5α-reductase activity in the prostate. Urology. 2001;58(6 Suppl 1):17–24.
31. Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem. 2006;99:333–344.
32. Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol. 2018;73(5);715–723.
33. Cai Z, Chen W, Zhang J, Li H. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer. Int Urol Nephrol. 2018;50(10):1753–1764.
34. Wyatt AW, Gleave ME. Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med. 2015;7(7):878–894.
35. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447–4454.
36. Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol. 2015;67:470–479.
37. Antonarakis ES, Armstrong AJ, Dehm SM, Luo J. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. Prostate Cancer Prostatic Dis. 2016;19:231–241.
38. Ho SM, Leung YK, Chung I. Estrogens and antiestrogens as etiological factors and therapeutics for prostate cancer. Ann. N. Y. Acad. Sci. 2006;1089:177–193.
39. Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids. 2008;73(3):233–244.
40. Hartman J, Ström A, Gustafsson JÅ. Current concepts and significance of estrogen receptor β in prostate cancer. Steroids. 2012;77:1262–1266.
41. Daniels G, Gellert LL, Melamed J, Hatcher D, Li Y, Wei J, Wang J, Lee P. Decreased expression of stromal estrogen receptor α and β in prostate cancer. Am J Transl Res. 2014;6:140–146.
42. Pisolato R, Lombardi APG, Vicente CM, Lucas TFG, Lazari MFM, Porto CS. Expression and regulation of the estrogen receptors in PC-3 human prostate cancer cells. Steroids. 2016;107:74–86.
43. Bradshaw AD. Diverse biological functions of the SPARC family of proteins. Int. J. Biochem. Cell Biol. 2012;44:480–488.
44. Murphy-Ullrich JE, Sage EH. Revisiting the matricellular concept. Matrix Biol. 2014;37:1–14.
45. Rosset EM, Bradshaw AD. SPARC/Osteonectin in Mineralized Tissue. Matrix Biol. 2016;52–54:78–87.
46. Kelm RJ Jr, Mann KG. The collagen binding specificity of bone and platelet osteonectin is related to differences in glycosylation. J. Biol. Chem. 1991;266:9632–9639.
47. Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, Martin GR. Osteonectin, a bone-specific protein linking mineral to collagen. Cell. 1981;26:99–105.
48. Delany AM, Hankenson KD. Thrombospondin-2 and SPARC/osteonectin are critical regulators of bone remodeling. J. Cell Commun. Signal. 2009;3:227–238.
49. Trombetta JM, Bradshaw AD. SPARC/Osteonectin Functions to Maintain Homeostasis of the Collagenous Extracellular Matrix in the Periodontal Ligament. J Histochem Cytochem. 2010;58(10):871–879.
50. Ingber D, Folkman J. Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: role of extracellular matrix. J Cell Biol. 1989;109:317–330.
51. Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res. 2000;6(3):1140–1149.
52. Brekken RA, Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 2001;19:816–827.
53. Breton-Gorius J, Clezardin P, Guichard J, Debili N, Malaval L, Vainchenker W, Cramer EM, Delmas PD. Localization of platelet osteonectin at the internal face of the alpha-granule membranes in platelets and megakaryocytes. Blood. 1992;79:936–941.
54. Reed MJ, Puolakkainen P, Lane TF, Dickerson D, Bornstein P, Sage EH. Differential expression of SPARC and thrombospondin 1 in wound repair: immunolocalization and in situ hybridization. J. Histochem. Cytochem. 1993;41:1467–1477.
55. Sage H, Johnson C, Bornstein P. Characterization of a novel serum albuminbinding glycoprotein secreted by endothelial cells in culture. J Biol Chem. 1984;259:3993–4007.
56. McCabe NP, Kerr BA, Madajka M, Vasanji A, Byzova TV. Augmented Osteolysis in SPARC-Deficient Mice with Bone-Residing Prostate Cancer. Neoplasia. 2011;13(1):31–39.
57. Ruela-Arispe M L, Lane T F, Redmond D, Reilly M, Bolender RP, Kavanagh TJ, Sage EH. Expression of SPARC during development of the chicken chorioallantoic membrane: evidence for regulated proteolysis in vivo. Mol. Biol. Cell. 1995;6: 327–343.
58. Burns-Cox N, Avery NC, Gingell JC, Bailey AJ. Changes in collagen metabolism in prostate cancer: a host response that may alter progression. J Urol. 2001;166(5):1698–1701.
59. Gao J, Song J, Huang H, Li Z, Du Y, Cao J, Li M, Lv S, Lin H, Gong Y. Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer. J Exp Clin Cancer Res. 2010;29(1):28.
60. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52–67.
61. Hynes RO, Naba A. Overview of the matrisome – an inventory of extracellular matrix constituents and functions. Cold Spring Harb Perspect Biol. 2012;4(1):a004903.
62. Cierna Z, Mego M, Janega P, Karaba M, Minarik G, Benca J, Sedlácková T, Cingelova S, Gronesova P, Manasova D, Pindak D, Sufliarsky J, Danihel L, Reuben JM, Mardiak J. Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer. BMC Cancer. 2014;14:472.
63. Mohan V, Talmi-Frank D, Arkadash V, Papo N, Sagi I. Matrix metalloproteinase protein inhibitors: highlighting a new beginning for metalloproteinases in medicine. Metalloproteinases in medicine. 2016;3:31–47.
64. Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia. 2010;15:201–212.
65. Mannello F. What does matrix metalloproteinase-1 expression in patients with breast cancer really tell us? BMC Med. 2011;9:95.
66. Hu F, Zhang Y, Li M, Zhao L, Chen J, Yang S, Zhang X. BMP-6 inhibits the metastasis of MDA-MB-231 breast cancer cells by regulating MMP-1 expression. Oncol. Rep. 2016;35:1823–1830.
67. Liu M, Hu Y, Zhang M-F, Luo K-J, Xie X-Y, Wen J, Fu JH, Yang H. MMP1 promotes tumor growth and metastasis in esophageal squamous cell carcinoma. Cancer Letters. 2016;377(1):97–104.
68. Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, Reiss M, Massagué J, Kang Y. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev. 2009;23:1882–1894
69. Casimiro S, Mohammad KS, Pires R, Tato-Costa J, Alho I, Teixeira R, Carvalho A, Ribeiro S, Lipton A, Guise TA, Costa L. RANKL/RANK/MMP-1 Molecular Triad Contributes to the Metastatic Phenotype of Breast and Prostate Cancer Cells In Vitro. PLoS One. 2013;8(5):e63153.
70. Ozden F, Saygin C, Uzunaslan D, Onal B, Durak H, Aki H. Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival. J. Cancer Res. Clin. Oncol. 2013;39:1373–1382.
71. Bianchi ME. Damps, pamps and alarmins: all we need to know about danger. J. Leukoc. Biol. 2007;81:1–5.
72. Min HJ, Choe JW, Chang MY, Kim KS, Lee SY, Mun SK. The expression and correlation of Hsp 70 and Hsp 27 in serous middle ear effusion fluids of pediatric patients-a preliminary study. International Journal of Pediatric Otorhinolaryngology. 2017;101:145–149.
73. Wu J, Liu T, Rios Z, Mei Q, Lin X, Cao S. Heat Shock Proteins and Cancer. Trends Pharmacol. Sci. 2017;38:226–256.
74. Gabai VL, Budagova KR, Sherman MY. Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents. Oncogene. 2005;24:3328.
75. Jindal DG, Jindal V, Joshi S, Bhojia I, Chawdhr A. Heat shock proteins in pathology: A review. Journal of Pierre Fauchard Academy (India Section). 2016;30(3–4):84–87.
76. Helmbrecht K, Zeise E, Rensing L. Chaperons in cell cycle regulation and mitogenic signal transduction: a review. Cell Prolif. 2000;92:1564.
77. Ni L, Yang CS, Gioeli D, Frierson H, Toft DO, Paschal BM. FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells. Mol Cell Biol. 2010;30(5):1243–1253.
78. Heinlein CA, Chang CS. Androgen receptor in prostate cancer. Endocr. Rev. 2004;25:276–308.
79. Kurahashi T, Miyake H, Hara I, Fujisawa M. Expression of Major Heat Shock Proteins in Prostate Cancer: Correlation With Clinicopathological Outcomes in Patients Undergoing Radical Prostatectomy. The Journal of Urology. 2007;177(2):757–761.
80. Narula S, Tandon S, Baligar P, Singh SK, Tandon C. Human kidney stone matrix: Latent potential to restrain COM induced cytotoxicity and inflammatory response. Chemico-Biological Interactions. 2017; 278:114–122.
81. Melman A. Synthesis of Inorganic Nanoparticles Using Protein Templates. Fine Particles in Medicine and Pharmacy. New York: Springer US, 2012, 340 p.
82. Chen E, Xue D, Zhang W, Lin F, Pan Z. Extracellular heat shock protein 70 promotes osteogenesis of human mesenchymal stem cells through activation of the ERK signaling pathway. FEBS Letters. 2015;589(24, parn B):4088–4096.
83. Fong-Ngern K, Sueksakit K, Thongboonkerd V. Surface heat shock protein 90 serves as a potential receptor for calcium oxalate crystal on apical membrane of renal tubular epithelial cells. J Biol Inorg Chem. 2016;21(4):463–74.
84. Li K, Xue Y, Chen A, Jiang Y, Xie H, Shi Q, Zhang S, Ni Y. Heat Shock Protein 90 Has Roles in Intracellular Calcium Homeostasis, Protein Tyrosine Phosphorylation Regulation, and Progesterone-Responsive Sperm Function in Human Sperm. PLoS One. 2014;9(12):e115841.
85. Kato K, Adachi S, Matsushima-Nishiwaki R, Minamitani C, Natsume H, Katagiri Y, Hirose Y, Mizutani J, Tokuda H, Kozawa O, Otsuka T. Regulation by Heat Shock Protein 27 of Osteocalcin Synthesis in Osteoblasts. Endocrinology. 2011;152(5):1872–1882.
86. Spierings D, McStay G, Saleh M, Bender C, Chipuk J, Maurer U, Green DR. Connected to death: the (unexpurgated) mitochondrial pathway of apoptosis. Science. 2005;310(5745):66–67.
87. Wajant H. The Fas signaling pathway: more than a paradigm. Science. 2002;296(5573):1635–1636.
88. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26(9):1324–1337.
89. Hu J, Duan Z, Yu G, Wang S. Bcl-2 Inhibitors as Sensitizing Agents for Cancer Chemotherapy. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy. 2019:151–168.
90. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature. 2009;458:1127–1130.
91. Thornton C, Hagberg H. Fetal and Neonatal Physiology (Fifth Edition). London: Elsevier, 2017, 1928 p.
92. Chappell WH, Lehmann BD, Terrian DM, Abrams SL, Steelman LS, McCubrey JA. p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. Cell Cycle. 2012;11(24):4579–4588.
93. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2010;2:a001107.
94. Chang YJ, Linh NH, Shih YH, Yu HM, Li MS, Chen YR. Alzheimer's amyloid-beta sequesters caspase-3 in vitro via its C-terminal tail. ACS Chem Neurosci. 2016;7:1097–1106.
95. Flanagan L, Meyer M, Fay J, Curry S, Bacon O, Duessmann H, John K, Boland KC, McNamara DA, Kay EW, Bantel H, Schulze-Bergkamen H, Prehn JH. Low levels of caspase-3 predict favourable response to 5FU-based chemotherapy in advanced colorectal cancer: caspase-3 inhibition as a therapeutic approach. Cell Death Dis. 2016;7:e2087.
96. Rodríguez-Berriguete G, Galvis L, Fraile B, de Bethencourt FR, Martínez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M. Immunoreactivity to caspase-3, caspase-7, caspase-8, and caspase-9 forms is frequently lost in human prostate tumors. Human Pathology. 2012;43:229–237.
97. Ashkenazi A, Salvesen G. Regulated Cell Death: Signaling and Mechanisms. Annual Review of Cell and Developmental Biology. 2014;30:337–356.
98. Bleicken S, Landeta O, Landajuela A, Basanez G, García-Saez AJ. Proapoptotic Bax and Bak Proteins Form Stable Protein-permeable Pores of Tunable Size. The journal of biological chemistry. 2013;288(46):33241–33252.
99. Rostamzadeh A, Ghadimi T, Allahveisi A, Mohammadi M, Rezaei S, Rezaie MJ. The expression of Bax protein in the early stages of spinal cord injury in the sperm cells of rats. Polish Annals of Medicine. 2018;25(2):196–202.
100. Snigdha S, Smith ED, Prieto GA, Cotman CW. Caspase-3 activation as a bifurcation point between plasticity and cell death. Neuroscience Bulletin. 2012;28(1):14–24.
101. Hernández-Luna MA, Díaz de León-Ortega R, Hernández-Cueto DD, Gaxiola-Centeno R, Castro-Luna R, Martínez-Cristóbal L, Huerta-Yépez S, Luria-Pérez R. Bactofection of sequences encoding a Bax protein peptide chemosensitizes prostate cancer tumor cells. Bol Med Hosp Infant Mex. 2016;73(6):388–396.
102. Maji S, Panda S, Samal S K, Shriwas O, Rath R, Pellecchia M, Emdad L, Das SK, Fisher PB, Dash R. Bcl-2 Antiapoptotic Family Proteins and Chemoresistance in Cancer. Advances in Cancer Research. 2018;137:37–75.
103. Westphal D, Kluck RM, Dewson G. Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis. Cell Death & Differentiation. 2014;21(2):196–205.
104. Yuan Z, Jiang H, Zhu X, Liu X, Li L. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer. Biomedicine & Pharmacotherapy. 2017;89:227–232.
105. Kervancioglu E, Kosan M, Erinanc H, Gonulalan U, Oguzulgen AI, Coskun EZ, Ozkardes H. Predictive values of vascular endothelial growth factor and microvessel-density levels in initial biopsy for prostate cancer. The Kaohsiung Journal of Medical Sciences. 2016;32(2):74–79.
106. Liu ZQ, Fang JM, Xiao YY, Zhao Y, Cui R, Hu F, Xu Q. Prognostic role of vascular endothelial growth factor in prostate cancer: A systematic review and meta-analysis. Int J Clin Exp Med. 2015;8:2289–2298.
107. Nordby Y, Andersen S, Richardsen E, Ness N, Al-Saad S, Melbø-Jørgensen C, Patel HR, Dønnem T, Busund LT, Bremnes RM. Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy. Prostate. 2015;75:1682–1693.
108. Rivera-Pérez J, Monter-Vera MDR, Barrientos-Alvarado C, Toscano-Garibay JD, Cuesta-Mejías T, Flores-Estrada J. Evaluation of VEGF and PEDF in prostate cancer: A preliminary study in serum and biopsies. Oncology Letters. 2018;15:1072–1078.
109. Djordjevic S, Driscoll PC. Targeting VEGF signalling via the neuropilin co-receptor. Drug Discov. Today. 2013;18:447–455.
110. Shibuya. M. VEGF-VEGFR signals in health and disease. Biomol Ther. 2014;22:1–9.
111. Roberts E, Cossigny DAF, Quan GMY. The Role of Vascular Endothelial Growth Factor in Metastatic Prostate Cancer to the Skeleton. Prostate Cancer. 2013:418340.
112. Gerber H-P, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossifcation and angiogenesis during endochondral bone formation. Nature Medicine. 1999;5(6):623–628.
113. Cossigny D, Quan GMY. In vivo animal models of spinal metastasis. Cancer and Metastasis Reviews. 2012;31(1):99–108.
114. Curtin P, Youm H, Salih E. Tree-dimensional cancerbone metastasis model using ex-vivo co-cultures of live calvarial bones and cancer cells. Biomaterials. 2012;33(4):1065–1078.
115. Karan D, Dubey S. From Inflammation to Prostate Cancer: The Role of Inflammasomes. Adv Urol. 2016;2016:3140372.
116. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867.
117. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–890.
118. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY, Sun HC. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008;26:2707–2716.
119. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362:875–885.
120. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell. 2009;15:416–428.
121. Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Molecular Cancer. 2013;12(1);86.
122. Mishra A, Shiozawa Y, Pienta KJ, Taichman RS. Homing of cancer cells to the bone. Cancer Microenviron. 2011,4:221–235.
123. Scimeca M, Urbano N, Rita B, Mapelli SN, Catapano CV, Carbone GM, Ciuffa S, Tavolozza M, Schillaci O, Mauriello A, Bonanno E. Prostate Osteoblast-Like Cells: A Reliable Prognostic Marker of Bone Metastasis in Prostate Cancer Patients. Contrast Media Mol Imaging. 2018;2018:9840962.
Published
2019-06-28
How to Cite
Piddubnyi, A. M., & Moskalenko, R. A. (2019). MOLECULAR ASPECTS OF THE BONE METASTASTASES DEVELOPMENT IN PROSTATE CANCER. Eastern Ukrainian Medical Journal, 7(2), 96-108. Retrieved from https://eumj.med.sumdu.edu.ua/index.php/journal/article/view/26
Section
Articles
This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN: 
